iLite® IL-12 Assay Ready Cells

Add to my product list

iLite® IL-12 Assay Ready Cells are a genetically engineered reporter gene cell line (DT-40, ATCC#CRL-2111) responsive to Interleukin-12 by specific and proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under the control of a constitutive promotor.

Product code
BM4012
Format
Assay Ready Cells
Calculation
Quantitative
Antigen
IL-12
Detection system
Luminescence
Availability
Research use only

The iLite®  IL-12 Assay Ready Cells can be used for the quantification IL-12 or p40 inhibitor activity, or neutralizing antibody response against such inhibitors in human serum. 
• Quantification of IL-12 inhibitor activity using iLite® IL-12 Assay Ready Cells (E-214-GB) 
• Determination of neutralizing antibodies against IL-12 inhibitors using iLite® IL-12 Assay Ready Cells (E-215-GB)

Interleukin 12 (IL-12) is a 70 kDa cytokine produced principally by macrophages, neutrophils and dendritic cells in response to stimulation by antigen. IL-12 is a T cell-stimulating factor, playing a critical role in the regulation of T-helper 1 cell responses. IL-12 is composed of two subunits, p35 and p40, covalently linked by a single disulfide bond. The p40 subunit, which binds to the receptor chain IL-12Rβ1, is shared with another heterodimeric cytokine, IL-23. However, the two cytokines expert distinct non-redundant biological functions (1). Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders (2).

>250 µL of iLite Assay Ready Cells suspended in RPMI 1640 medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).